Glaxosmithkline

Fire disrupts production at GSK Pharma's contract manufacturing site

GSK Pharmaceuticals has reported a fire at one of its contract sites, causing temporary disruption; the company is assessing the impact and working to restore operations

Trend turns favourable for GlaxoSmithKline Pharma, key levels to track

GlaxoSmithKline Pharma stock has seen formation of 'Golden Cross' on the daily chart on Thursday; last time the stock saw a similar development, it rallied almost 117% over the next 14 months.

GlaxoSmithKline Pharma Q3FY25: Net profit rises 400% to Rs 228.58 crore

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024. The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement. "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added. The company saw strong performance across key product portfolios during the quarter, the drug firm said. Flagship brands within the genera

Delaware judge allows more than 70,000 Zantac lawsuits to go forward

In 2019, some manufacturers and pharmacies halted Zantac sales after a chemical called NDMA, which is known to cause cancer, was detected in some pills

GlaxoSmithKline sues Pfizer, BioNTech over Covid-19 vaccine technology

GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of COVID-19

GlaxoSmithKline Pharma Q3 results: Profit declines 72% to Rs 46 crore

GlaxoSmithKline Pharmaceuticals on Monday said its consolidated net profit declined 72 per cent to Rs 46 crore for the December quarter. The drug firm had reported a net profit of Rs 165 crore in the year-ago period. Total income increased to Rs 833 crore for the third quarter of the current fiscal as compared with Rs 826 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement. "We remain committed to new category development in areas like adult immunisation with products like Shingrix to make a positive impact to the lives of the patients in India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. The company would continue to drive operational efficiency and explore new innovative solutions, including omnichannel strategy, to expand reach and coverage to the target segments, he added. Shares of the drugmaker declined 1.91 per cent to Rs 2,334.20 apiece on the BSE on Monday.

Imperial College London appoints Manvinder Banga as its chair of council

Banga has also held the position of Senior Independent Director at retail chain Marks and Spencer plc and at GlaxoSmithKline

GlaxoSmithKline board okays VRS scheme as part of biz review

GlaxoSmithKline Pharmaceuticals on Thursday said its board has approved a Voluntary Retirement Scheme (VRS) for a certain segment of employees under a strategic review of the business. In a regulatory filing, the drug firm said its board has approved a commercial transformation initiative as part of a strategic review of the business. "As part of the transformation and to continue to remain competitive, the company will explore new innovative solutions, including omnichannel strategy, to expand its reach and coverage to the target segments," the drug firm said. Further, the company has launched a voluntary retirement scheme for commercial function employees in field sales and head office. The initiative includes provisions for financial and transition support. The financial impact will be communicated separately, GlaxoSmithKline Pharmaceuticals said.

GlaxoSmithKline Pharma consolidated Q1 net profit rises 11% to Rs 132 cr

GlaxoSmithKline Pharmaceuticals on Wednesday said its consolidated net profit increased by 11 per cent to Rs 132 crore for the first quarter ended June 30. The drug maker had reported a net profit of Rs 119 crore in the April-June quarter of the last fiscal. Its total income rose to Rs 798 crore in the first quarter against Rs 773 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "Despite the strong external headwinds, GSK remains focused on delivering best-in-class competitive performance and driving operational efficiencies. We remain committed to explore new growth opportunities and improving our leadership in key therapy areas," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar said. Shares of the company were trading 0.3 per cent down at Rs 1,399.20 apiece on the BSE.

Whirlpool net profit down 24.6% YoY to Rs 63.7 crore in Jan-Mar quarter

Consumer durables maker Whirlpool of India Ltd on Wednesday reported a 24.58 per cent decline in its consolidated net profit at Rs 63.71 crore for the fourth quarter ended March 2023. The company had posted a net profit of Rs 84.48 crore during the January-March quarter of the previous fiscal, Whirlpool of India, a subsidiary of Whirlpool Corporation said in a regulatory filing. Its revenue from operations was down 2 per cent to Rs 1,672.65 crore during the quarter under review against Rs 1,706.91 crore in the corresponding period of the previous fiscal. Whirlpool of India's total expenses were at Rs 1,624.89 crore in the quarter, up 1.08 per cent over the year-ago period. Its total income in the March quarter was marginally down to Rs 1,704.94 crore. Consolidated financial results comprise the financial results of the company and its subsidiary Elica PB, a kitchen appliances maker, which it had acquired in FY2021-22, it said. For the fiscal year ended March 2023, Whirlpool of In

GlaxoSmithKline Pharma's pre-tax profit falls 8% on govt pricing caps

India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines

GlaxoSmithKline Pharma posts net profit at Rs 133 crore in Jan-Mar quarter

GlaxoSmithKline Pharmaceuticals Ltd on Wednesday reported a consolidated net profit from continuing operations at Rs 133.43 crore in the fourth quarter ended March 2023. The company had posted a consolidated net loss from continuing operations at Rs 54.66 crore a year ago, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing. Its consolidated revenue from continuing operations stood at Rs 787.45 crore against Rs 809.63 crore in the year-ago period. The total expenses in the quarter were higher at Rs 635.54 crore compared to Rs 650.04 crore in the corresponding period of the previous year. For FY23, consolidated net profit from continuing operations was Rs 607.64 crore against Rs 380.77 crore in FY22. The company said its consolidated revenue from continuing operations stood at Rs 3,251.72 crore in FY23 compared to Rs 3,278.03 crore in FY22. General medicine portfolio saw double-digit underlying growth and the company continued to maintain market leadership in

NPPA to cap medicine prices to boost affordability, curb profiteering

The change could have financial implications for leading drug manufacturers like Abbott Laboratories, Bayer AG, and GlaxoSmithKline, among others

Rs 10 lakh penalty imposed on Glaxo Smith Kline for misleading ad

The Central Consumer Protection Authority (CCPA) has imposed a penalty of Rs 10 lakh each on Glaxo Smith Kline and Naaptol for misleading advertisements of their products.

GlaxoSmithKline Pharma Q2 net up 3% to Rs 193 cr, revenue down to Rs 906 cr

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased 3 per cent to Rs 193 crore in the second quarter ended September. The drug maker had reported a net profit from continuing operations at Rs 187 crore in the July-September period of the previous fiscal. However, revenue from operations declined to Rs 906 crore in the second quarter of the current fiscal compared to Rs 916 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a regulatory filing. "GSK India has delivered another quarter of strong performance in general medicines and specialty business, gaining market share. We hope to build on this momentum in the coming quarters and continue to focus on our key brands to drive sustainable profitable growth," GlaxoSmithKline Pharmaceuticals Managing Director Sridhar Venkatesh said. Vaccines business was impacted due to low vaccination rates as the overall market for the self-pay segment in which the company operates continues to decline, he ...

India-made cervical cancer vaccine Ceravac to cost Rs 200-400 per dose

Serum India's product made in collaboration with state-run biotechnology department, expected to bring down prices

Glaxosmithkline Pharma Q1 consolidated net profit up 8% at Rs 116 crore

Drug manufacturers GlaxoSmithKline on Monday said its consolidated net profit increased to Rs 116 crore in the first quarter. Shares of the company closed at Rs 1,726.20 on BSE, said reports

Unilever faces fresh pressure over margins as it backs down on M&A

Unilever sees 2022 underlying sales growth of 4.5%-6.5%, announces 3-bn euro buyback

CCI approves deal involving three GlaxoSmithKline group entities

The proposed deal involves the transfer of GlaxoSmithKline Asia Pvt Ltd's products and GSK Consumer Brands (indirectly) to GSK CH HoldCo

Covid: GSK says tests show antibody drug works against Omicron variant

Sotrovimab, developed with Vir, tested in lab, on hamsters; key mutations of Omicron did not elude drug activity in study